Skip to main content
. 2023 Dec 20;6(12):e2347886. doi: 10.1001/jamanetworkopen.2023.47886

Table 1. Demographics, Baseline Data, and Procedure Timea.

Characteristic Esketamine (nā€‰=ā€‰331) Placebo (nā€‰=ā€‰329) SMD
Age, median (IQR), y 48 (36-57) 47 (37-57) 0.002
Sex
Female 195 (58.9) 160 (48.6) 0.21
Male 136 (41.1) 169 (51.4)
Height, median (IQR), m 1.65 (1.6-1.7) 1.67 (1.6-1.7) 0.21
Weight, median (IQR), kg 62 (55-70) 63 (57-72) 0.18
BMI, median (IQR) 22.9 (21.1-24.9) 23.2 (21.5-24.9) 0.08
ASA physical status
I 257 (77.6) 242 (73.6) 0.10
II 74 (22.4) 87 (26.4)
Current smoker 28 (8.5) 35 (10.6) 0.07
Hypertension 41 (12.4) 55 (16.7) 0.12
Diabetes 21 (6.3) 29 (8.8) 0.09
Baseline measurements
SBP, median (IQR), mm Hg 129 (118-141) 128 (120-141) 0.005
DBP, mean (SD), mm Hg 75.4 (11.0) 75.7 (11.2) 0.03
MAP, mean (SD), mm Hg 93.7 (11.9) 93.9 (11.5) 0.02
HR, median (IQR), beats per min 76 (68-84) 75 (70-82) 0.03
Spo2, median (IQR), % 100 (99-100) 100 (99-100) 0.02
Trial sites
Site 1 220 (66.5) 220 (66.9) 0.01
Site 2 56 (16.9) 54 (16.4)
Site 3 55 (16.6) 55 (16.7)
Procedure time, median (IQR), min 20 (16-25) 18 (15-22) 0.15

Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; SBP, systolic blood pressure; SMD, standardized mean difference; Spo2, oxygen saturation as measured by pulse oximetry.

a

Data are presented as number (percentage) of patients unless otherwise indicated.